肺腺癌中缺氧诱导因子-1α调控程序性死亡因子配体1的表达

doi:10.6040/j.issn.1671-7554.0.2016.1467

Abstract

Abstract: Objective To analyze the association of hypoxia-inducible factor-1α(HIF-1α)and programmed death ligand 1(PD-L1)expression and clinicopathologic features in lung adenocarcinoma, and to investigate the potential role of HIF-1α in the regulation of PD-L1 expression. Methods The expressions of HIF-1α and PD-L1 of 99 cases with lung adenocarcinoma were examined by immunohistochemical method. The lung adenocarcinoma cells were treated with hypoxia mimic CoCl₂ and divided into normal group and CoCl₂ group. The mRNA and protein expressions of HIF-1α and PD-L1 were detected with qRT-PCR and Western blotting, respectively. The lung adenocarcinoma cells were transfected with siRNA-HIF-1α and divided into negative control group and siR-HIF-1α group. The transfection efficiency of siRNAs and the expression of PD-L1 were detected by qRT-PCR and Western blotting, respectively. Results The positive expression rates of HIF-1α and PD-L1 were 47.48% and 34.34% in 99 cases with lung adenocarcinoma, respec- 山东大学学报 (医学版)55卷4期 -张智慧,等.肺腺癌中缺氧诱导因子-1α调控程序性死亡因子配体1的表达 \=-tively. The expression of HIF-1α was correlated with age and clinical stage(P<0.05). The expression of PD-L1 was correlated with clinical stage(P<0.05). The expressions of HIF-1α and PD-L1 were positive correlated(P<0.01). Compared with the normal group, the protein expression of HIF-1α significantly increased(t=-2.394, P=0.029), and the mRNA and protein expressions of PD-L1 increased subsequently in the CoCl₂ group(t=-3.146, P=0.006; t=-3.308, P=0.004). Compared with the negative control group, the mRNA and protein expressions of PD-L1 decreased dramatically in the siR-HIF-1α group(t=2.746, P=0.014; t=2.339, P=0.033). Conclusion The HIF-1α and PD-L1 proteins are highly co-expressed, and HIF-1α can up-regulate the expression of PD-L1 in lung adenocarcinoma.

Key words: Hypoxia-inducible factor-1α, Programmed death ligand 1, Lung adenocarcinoma

CLC Number:

R734.2

ZHANG Zhihui, WANG Lili, GAO Hua, ZHANG Jian, LI Juan, LI Yuan, WU Chunxiao, LU Zhiming. Role of hypoxia-inducible factor-1α in the regulation of programmed death ligand 1 expression in lung adenocarcinoma[J].JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 65-70.

References

[1] Zheng YW, Li RM, Zhang XW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome[J]. Cancer Invest, 2013, 31(3): 197-205.
[2] Lortet-Tieulent J, Soerjomataram I, Ferlay J, et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women[J]. Lung Cancer, 2014, 84(1): 13-22.
[3] Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800.
[4] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
[5] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135.
[6] Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(21): 2018-2028.
[7] Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer[J]. Lung Cancer, 2016, 99(2016): 79-87.
[8] Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review[J]. JAMA Oncol, 2016, 2(9): 1217-1222.
[9] Bally AP, Austin JW, Boss JM. Genetic and epigenetic regulation of PD-1 expression[J]. J Immunol, 2016, 196(6): 2431-2437.
[10] Semenza GL. Oxygen sensing, homeostasis, and disease[J]. N Engl J Med, 2011, 365(6): 537-547.
[11] Barsoum IB, Smallwood CA, Siemens DR, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells[J]. Cancer Res, 2014, 74(3): 665-674.
[12] Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J]. J Exp Med, 2014, 211(5): 781-790.
[13] Chang YL, Yang CY, Lin MW, et al. High co-expression of PD-L1 and HIF-1α correlates with tumor necrosis in pulmonary pleomorphic carcinoma[J]. Eur J Cancer, 2016, 60:125-135.
[14] Chen TC, Wu CT, Wang CP, et al. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof[J]. Oral Oncol, 2015, 51(11): 1004-1010.
[15] Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming(seventh)edition of the TNM classification of malignant tumors[J]. J Thorac Oncol, 2007, 2(8): 694-705.
[16] Kishimoto K, Yoshida S, Ibaragi S, et al. Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer[J]. Oral Oncol, 2012, 48(11): 1120-1127.
[17] Urano N, Fujiwara Y, Doki Y, et al. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma[J]. Gastric Cancer, 2006, 9(1): 44-49.
[18] Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation[J]. Pancreas, 2008, 36(3): 1-9.
[19] Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer[J]. Endocr Relat Cancer, 2006, 13(3): 739-749.
[20] Liu SY, Chang LC, Pan LF, et al. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma[J]. Oral Oncol, 2008, 44(3): 277-285.
[21] Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy[J]. Acta Pharm Sin B, 2015, 5(5): 378-389.
[22] Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis[J]. Cell Death Differ, 2008, 15(4): 678-685.
[23] Rankin EB, Giaccia AJ. Hypoxic control of metastasis[J]. Science, 2016, 352(6282): 175-180.
[24] Palazon A, Goldrath AW, Nizet V, et al. HIF transcription factors, inflammation, and immunity[J]. Immunity, 2014, 41(4): 518-528.
[25] 刘金峰, 张楠, 徐超, 等. HIF-1α与HGF在非小细胞肺癌中的共表达及其与淋巴管生成的关系[J]. 山东大学学报(医学版), 2011, 49(11): 112-116. LIU Jinfeng, ZHANG Nan, XU Chao, et al. Co-expression of hypoxia-inducible factor-1α and hepatocyte growth factor in non-small-cell lung cancer and their association with lymphangiogenesis[J]. Journal of Shandong University(Health Sciences), 2011, 49(11): 112-116.
[26] 张浩, 任秀红, 刘莉. PD-L1和EGFR在非小细胞肺癌组织中的表达及相关性分析[J]. 疑难病杂志, 2015, 14(8): 786-792. ZHANG Hao, REN Xiuhong, LIU Li. Expression of PD-L1 and EGFR in non-small cell lung cancer and its clinical relationships[J]. Chin J Diffic and Compl Cas, 2015, 14(8): 786-792.
[27] Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma[J]. Int J Cancer, 2016, 139(2): 396-403.
[28] Koh J, Jang JY, Keam B, et al. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor(HIF)-1α and STAT3[J]. Oncoimmunology, 2015, 5(3): e1108514.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Role of hypoxia-inducible factor-1α in the regulation of programmed death ligand 1 expression in lung adenocarcinoma

PDF (PC)

Abstract

Cite this article

share this article

References

Related Articles 8

Metrics

Comments

Recommended 0

[1]	TANG Xi, HU Ya, XU Yanhua, WANG Chunlin, QIU Ping, WANG Xianghui. MiR- 498 inhibits A549 cells EMT by targeting FOXM1 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 39-43.
[2]	SUN Jie, MU Xiaoyan, DONG Xueli. Combinational and sequential effect of sunitinib and gemcitabine on K-RAS mutant A549 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 45-49.
[3]	DONG Xue-li, MU Xiao-yan, LIU Qing-liang, SUN Jie. Effects of erlotinib combined with celecoxib on growth and angiogenesis of human lung cancer xenograft model [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(2): 49-52.
[4]	FAN Heng-jian, ZHANG Yu-ke, XIAO Wei, ZHANG Yi, LI Hai-jun, WANG De-xiang. Changes of Treg and Th17 cells in the peripheral bloods of patients with lung adenocarcinoma and their prognostic significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 73-78.
[5]	MA Yu-hua1,2, ZHENG Yan3, JIA Yan-fei3, WANG Yun-shan3. GFR and DEC1 protein co-expression promotes lymph node metastasis in lung adenocarcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 24-28.
[6]	LI Haijun, XIAO Wei. Increased frequency of Th17 cells in the peripheral blood of patients with lung adenocarcinoma and its clinical significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(8): 108-112.
[7]	L V Yi-jing, REN Min, WANG Bo, GE Ru-qing, ZHANG Ji-dong. Expressions of EZH2 and CTGF Gene in lung adenocarcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(5): 94-97.
[8]	YU Fang,ZHOU Geng-yin,ZHANG Cui-juan,GAO Peng,MA Chao,LI Hong. Expression of HIF-1α and P-gp and their correlation in patients with hepatocellular carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 246-249.